Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Anterior gradient 2 and mucin 4 expression mirrors tumor cell differentiation in pancreatic adenocarcinomas, but aberrant anterior gradient 2 expression predicts worse patient outcome in poorly differentiated tumors.

Brychtova V, Hermanova M, Karasek P, Lenz J, Selingerova I, Vojtesek B, Kala Z, Hrstka R.

Pancreas. 2014 Jan;43(1):75-81. doi: 10.1097/MPA.0b013e3182a63bc3.

PMID:
24177142
2.

Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma.

Riener MO, Pilarsky C, Gerhardt J, Gr├╝tzmann R, Fritzsche FR, Bahra M, Weichert W, Kristiansen G.

Histol Histopathol. 2009 Sep;24(9):1121-8. doi: 10.14670/HH-24.1121.

PMID:
19609859
3.

CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.

Lee SH, Kim H, Hwang JH, Shin E, Lee HS, Hwang DW, Cho JY, Yoon YS, Han HS, Cha BH.

Pancreas. 2014 Apr;43(3):380-8. doi: 10.1097/MPA.0000000000000097.

PMID:
24622067
4.

Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.

Tsutsumi K, Sato N, Tanabe R, Mizumoto K, Morimatsu K, Kayashima T, Fujita H, Ohuchida K, Ohtsuka T, Takahata S, Nakamura M, Tanaka M.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S491-9. doi: 10.1245/s10434-011-1970-2. Epub 2011 Aug 12.

PMID:
21837532
5.

Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.

Lenz J, Karasek P, Jarkovsky J, Muckova K, Dite P, Kala Z, Veselska R, Hermanova M.

J Gastrointestin Liver Dis. 2011 Dec;20(4):389-96.

6.
7.

Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas.

Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M.

Mod Pathol. 2011 Sep;24(9):1237-47. doi: 10.1038/modpathol.2011.74. Epub 2011 May 6.

8.

Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition.

Mizuuchi Y, Aishima S, Ohuchida K, Shindo K, Fujino M, Hattori M, Miyazaki T, Mizumoto K, Tanaka M, Oda Y.

Lab Invest. 2015 Feb;95(2):193-206. doi: 10.1038/labinvest.2014.138. Epub 2014 Nov 24.

9.

EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins.

Handra-Luca A, Hammel P, Sauvanet A, Lesty C, Ruszniewski P, Couvelard A.

J Clin Pathol. 2014 Apr;67(4):295-300. doi: 10.1136/jclinpath-2013-201662. Epub 2013 Oct 29.

PMID:
24170210
10.

Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.

Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, Goggins MS, Abbruzzese JL, Maitra A, Ho L.

Mod Pathol. 2007 May;20(5):570-8. Epub 2007 Mar 30.

11.

Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.

Liu C, Yang Z, Li D, Liu Z, Miao X, Yang L, Zou Q, Yuan Y.

Cancer Biomark. 2015;15(6):735-43. doi: 10.3233/CBM-150515.

PMID:
26406402
12.

Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.

Park HU, Kim JW, Kim GE, Bae HI, Crawley SC, Yang SC, Gum JR Jr, Batra SK, Rousseau K, Swallow DM, Sleisenger MH, Kim YS.

Pancreas. 2003 Apr;26(3):e48-54.

PMID:
12657964
13.

The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma.

Zhu Y, Zhang JJ, Zhu R, Zhu Y, Liang WB, Gao WT, Yu JB, Xu ZK, Miao Y.

Med Oncol. 2011 Dec;28 Suppl 1:S175-84. doi: 10.1007/s12032-010-9683-0. Epub 2010 Oct 5.

PMID:
20922503
14.

Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.

Xie H, Lin J, Thomas DG, Jiang W, Liu X.

Int J Clin Exp Pathol. 2012;5(4):347-55. Epub 2012 Apr 16.

15.

L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.

Tsutsumi S, Morohashi S, Kudo Y, Akasaka H, Ogasawara H, Ono M, Takasugi K, Ishido K, Hakamada K, Kijima H.

J Surg Oncol. 2011 Jun 1;103(7):669-73. doi: 10.1002/jso.21880. Epub 2011 Feb 28.

PMID:
21360711
16.

Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.

Qi T, Han J, Cui Y, Zong M, Liu X, Zhu B.

J Clin Pathol. 2008 Jan;61(1):49-58. Epub 2007 Apr 5.

PMID:
17412869
17.
18.

High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.

Chen HT, Cai QC, Zheng JM, Man XH, Jiang H, Song B, Jin G, Zhu W, Li ZS.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S464-74. doi: 10.1245/s10434-011-1968-9. Epub 2011 Aug 6.

PMID:
21822553
19.

Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia.

Brody JR, Witkiewicz A, Williams TK, Kadkol SS, Cozzitorto J, Durkan B, Pasternack GR, Yeo CJ.

Mod Pathol. 2007 Dec;20(12):1238-44. Epub 2007 Sep 28.

20.

Mitochondrial transcription factor a worsens the clinical course of patients with pancreatic cancer through inhibition of apoptosis of cancer cells.

Yamauchi M, Nakayama Y, Minagawa N, Torigoe T, Shibao K, Yamaguchi K.

Pancreas. 2014 Apr;43(3):405-10. doi: 10.1097/MPA.0000000000000049.

PMID:
24622070

Supplemental Content

Support Center